AbbVie Inc. (NYSE:ABBV) is one of the best performing pharma stocks in 2025 but was downgraded to Peer Perform from Outperform by Wolfe Research on January 8. AbbVie denied involvement in talks to acquire Revolution Medicines, despite reports. UBS assumed coverage of AbbVie with a Neutral rating and $240 price target.

AbbVie develops and sells products to treat chronic diseases in various areas. While it has investment potential, some AI stocks may offer greater upside with less downside risk. For more information on short-term AI stocks, check out a free report available.

No promotional or marketing information was included in the news article.

Read more at Yahoo Finance: AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research